ID

34473

Descripción

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach; ODM derived from: https://clinicaltrials.gov/show/NCT01138527

Link

https://clinicaltrials.gov/show/NCT01138527

Palabras clave

  1. 17/1/19 17/1/19 -
  2. 27/5/19 27/5/19 -
Titular de derechos de autor

see on clinicaltrials.gov

Subido en

17 de enero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Prostate Cancer NCT01138527

Eligibility Prostate Cancer NCT01138527

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
biopsy-proven diagnosis of adenocarcinoma of the prostate
Descripción

ID.1

Tipo de datos

boolean

subject will sign a consent form prior to study entry
Descripción

ID.2

Tipo de datos

boolean

radical prostatectomy and histopathological exam planned
Descripción

ID.3

Tipo de datos

boolean

the time interval between last biopsy and the mr exam must be at least 4 weeks
Descripción

ID.4

Tipo de datos

boolean

the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
Descripción

ID.5

Tipo de datos

boolean

Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects who are unable to give valid informed consent
Descripción

ID.6

Tipo de datos

boolean

subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
Descripción

ID.7

Tipo de datos

boolean

therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
Descripción

ID.8

Tipo de datos

boolean

patients under hormone deprivation therapy.
Descripción

ID.9

Tipo de datos

boolean

Similar models

Eligibility Prostate Cancer NCT01138527

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
biopsy-proven diagnosis of adenocarcinoma of the prostate
boolean
ID.2
Item
subject will sign a consent form prior to study entry
boolean
ID.3
Item
radical prostatectomy and histopathological exam planned
boolean
ID.4
Item
the time interval between last biopsy and the mr exam must be at least 4 weeks
boolean
ID.5
Item
the time interval between mr exam and radical prostatectomy should not exceed 12 weeks
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
subjects who are unable to give valid informed consent
boolean
ID.7
Item
subjects who are unwilling or unable to undergo an mr exam, including subjects with contra-indications to mr exams
boolean
ID.8
Item
therapy or surgical procedure applied to the prostate or to other organs in vicinity to the prostate: among the therapies preventing inclusion are any form of radiation therapy, cryo-therapy, thermal-therapy, therapy based on any other medication (including hormonal therapy).
boolean
ID.9
Item
patients under hormone deprivation therapy.
boolean

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial